ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 67 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $428,981 | -22.0% | 70,964 | +0.1% | 0.00% | 0.0% |
| Q2 2023 | $549,937 | +82.1% | 70,860 | +245.1% | 0.00% | +100.0% |
| Q4 2021 | $302,000 | -1.3% | 20,536 | +40.3% | 0.00% | 0.0% |
| Q3 2021 | $306,000 | +36.6% | 14,635 | +59.9% | 0.00% | 0.0% |
| Q1 2021 | $224,000 | -27.7% | 9,153 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $310,000 | +54.2% | 9,153 | +13.7% | 0.00% | 0.0% |
| Q3 2020 | $201,000 | -4.7% | 8,047 | +28.4% | 0.00% | 0.0% |
| Q2 2020 | $211,000 | – | 6,265 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |